Alethia Young
Stock Analyst at Cantor Fitzgerald
(2.93)
# 1,418
Out of 5,152 analysts
135
Total ratings
53.64%
Success rate
31.05%
Average return
Main Sectors:
Stocks Rated by Alethia Young
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCUS Arcus Biosciences | Reiterates: Overweight | n/a | $22.68 | - | 5 | Jul 5, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Overweight | n/a | $65.10 | - | 5 | Jun 20, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $800 → $850 | $787.50 | +7.94% | 9 | Oct 16, 2023 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | $18 | $2.19 | +721.92% | 6 | Sep 12, 2023 | |
| CRIS Curis | Reiterates: Overweight | $60 | $1.04 | +5,669.23% | 3 | Sep 7, 2023 | |
| ELDN Eledon Pharmaceuticals | Reiterates: Overweight | $9 | $2.51 | +258.57% | 2 | Aug 22, 2023 | |
| VSTM Verastem | Reiterates: Overweight | $34 | $5.81 | +485.20% | 2 | Jul 6, 2023 | |
| BIIB Biogen | Maintains: Neutral | $427 → $327 | $189.94 | +72.16% | 7 | Oct 15, 2021 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $285 → $281 | $477.89 | -41.20% | 5 | Jun 11, 2021 | |
| AKBA Akebia Therapeutics | Initiates: Overweight | $8 | $1.25 | +540.00% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $98 | $1.45 | +6,658.62% | 3 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $295 | $379.27 | -22.22% | 9 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $84 → $86 | $148.22 | -41.98% | 3 | Oct 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $48 | $29.19 | +64.44% | 4 | Oct 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $5.63 | +432.86% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $72 | $28.19 | +155.41% | 8 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $5 | $1.56 | +220.51% | 5 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $83 → $100 | $98.86 | +1.15% | 6 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $185 → $201 | $241.38 | -16.73% | 6 | Apr 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $86 → $85 | $64.29 | +32.21% | 5 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $32 | $15.04 | +112.77% | 1 | Mar 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $211 → $217 | $16.09 | +1,248.66% | 12 | Feb 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $48 | $60.55 | -20.73% | 4 | Oct 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $14.58 | - | 3 | Mar 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $151 → $154 | $327.30 | -52.95% | 5 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $113 → $116 | $60.43 | +91.96% | 2 | Mar 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $147 → $106 | $6.40 | +1,556.25% | 8 | Jan 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $28 | $13.82 | +102.60% | 1 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $82 | $203.41 | -59.69% | 2 | Sep 27, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | n/a | $490.21 | - | 1 | Mar 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.84 | - | 1 | Oct 18, 2016 |
Arcus Biosciences
Jul 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $22.68
Upside: -
Arrowhead Pharmaceuticals
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $65.10
Upside: -
Regeneron Pharmaceuticals
Oct 16, 2023
Maintains: Neutral
Price Target: $800 → $850
Current: $787.50
Upside: +7.94%
ALX Oncology Holdings
Sep 12, 2023
Reiterates: Overweight
Price Target: $18
Current: $2.19
Upside: +721.92%
Curis
Sep 7, 2023
Reiterates: Overweight
Price Target: $60
Current: $1.04
Upside: +5,669.23%
Eledon Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $9
Current: $2.51
Upside: +258.57%
Verastem
Jul 6, 2023
Reiterates: Overweight
Price Target: $34
Current: $5.81
Upside: +485.20%
Biogen
Oct 15, 2021
Maintains: Neutral
Price Target: $427 → $327
Current: $189.94
Upside: +72.16%
Vertex Pharmaceuticals
Jun 11, 2021
Maintains: Overweight
Price Target: $285 → $281
Current: $477.89
Upside: -41.20%
Akebia Therapeutics
Mar 8, 2021
Initiates: Overweight
Price Target: $8
Current: $1.25
Upside: +540.00%
Feb 25, 2021
Maintains: Overweight
Price Target: $86 → $98
Current: $1.45
Upside: +6,658.62%
Feb 3, 2021
Maintains: Overweight
Price Target: $280 → $295
Current: $379.27
Upside: -22.22%
Oct 29, 2020
Reiterates: Overweight
Price Target: $84 → $86
Current: $148.22
Upside: -41.98%
Oct 28, 2020
Maintains: Overweight
Price Target: $30 → $48
Current: $29.19
Upside: +64.44%
Oct 12, 2020
Initiates: Overweight
Price Target: $30
Current: $5.63
Upside: +432.86%
Jul 31, 2020
Maintains: Overweight
Price Target: $70 → $72
Current: $28.19
Upside: +155.41%
Jun 2, 2020
Assumes: Overweight
Price Target: $5
Current: $1.56
Upside: +220.51%
May 19, 2020
Maintains: Neutral
Price Target: $83 → $100
Current: $98.86
Upside: +1.15%
Apr 20, 2020
Reiterates: Overweight
Price Target: $185 → $201
Current: $241.38
Upside: -16.73%
Apr 8, 2020
Reiterates: Overweight
Price Target: $86 → $85
Current: $64.29
Upside: +32.21%
Mar 6, 2020
Maintains: Overweight
Price Target: $30 → $32
Current: $15.04
Upside: +112.77%
Feb 27, 2020
Reiterates: Overweight
Price Target: $211 → $217
Current: $16.09
Upside: +1,248.66%
Oct 3, 2019
Maintains: Neutral
Price Target: $75 → $48
Current: $60.55
Upside: -20.73%
Mar 22, 2018
Downgrades: Underperform
Price Target: n/a
Current: $14.58
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $151 → $154
Current: $327.30
Upside: -52.95%
Mar 2, 2018
Maintains: Outperform
Price Target: $113 → $116
Current: $60.43
Upside: +91.96%
Jan 24, 2018
Maintains: Outperform
Price Target: $147 → $106
Current: $6.40
Upside: +1,556.25%
Nov 3, 2017
Maintains: Outperform
Price Target: $24 → $28
Current: $13.82
Upside: +102.60%
Sep 27, 2017
Maintains: Neutral
Price Target: $85 → $82
Current: $203.41
Upside: -59.69%
Mar 16, 2017
Initiates: Underperform
Price Target: n/a
Current: $490.21
Upside: -
Oct 18, 2016
Initiates: Outperform
Price Target: n/a
Current: $2.84
Upside: -